Latest Articles
Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab Plus Chemo Expands Frontline Options in Advanced/Recurrent Endometrial Cancer OncLive
Published: Sept. 24, 2025, 7:04 p.m.
UNM physician gets $12.9M grant to study endometrial cancer - KOB.com
UNM physician gets $12.9M grant to study endometrial cancer KOB.com
Published: Sept. 24, 2025, 5:39 p.m.
UNM Cancer Center Physician-Scientist Awarded $12.9M Grant to Study Endometrial Cancer | Newswise - Newswise
UNM Cancer Center Physician-Scientist Awarded $12.9M Grant to Study Endometrial Cancer | Newswise Newswise
Published: Sept. 24, 2025, 12:05 p.m.
Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Are Crucial for Endometrial Cancer Risk Reduction - OncLive
Spotlighting Disease Prevention Efforts Alongside Treatment Breakthroughs Are Crucial for Endometrial Cancer Risk Reduction OncLive
Published: Sept. 23, 2025, 8:09 p.m.
Jemperli Scores Korean Coverage Ahead of Keytruda in Endometrial Cancer - NAVLIN DAILY
Jemperli Scores Korean Coverage Ahead of Keytruda in Endometrial Cancer NAVLIN DAILY
Published: Sept. 22, 2025, 11:27 p.m.
Air-Heated Blankets Improved Hypothermia Rates During Endometrial Cancer Resection - Cancer Nursing Today
Air-Heated Blankets Improved Hypothermia Rates During Endometrial Cancer Resection Cancer Nursing Today
Published: Sept. 19, 2025, 8:50 p.m.
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer - The ASCO Post
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer The ASCO Post
Published: Sept. 19, 2025, 2:31 p.m.
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes - The ASCO Post
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes The ASCO Post
Published: Sept. 19, 2025, 2:23 p.m.
Signs of endometrial cancer you shouldn’t ignore - Geisinger Health System
Signs of endometrial cancer you shouldn’t ignore Geisinger Health System
Published: Sept. 19, 2025, 12:31 p.m.
Latecomer Jemperli wins reimbursement race against Keytruda for endometrial cancer in Korea - koreabiomed.com
Latecomer Jemperli wins reimbursement race against Keytruda for endometrial cancer in Korea koreabiomed.com
Published: Sept. 19, 2025, 4:21 a.m.
Link copied to clipboard!